미국 - 영어 - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - clonidine hydrochloride (unii: w76i6xxf06) (clonidine - unii:mn3l5rmn02) - clonidine hydrochloride 0.3 mg - clonidine hydrochloride tablets, usp are indicated in the treatment of hypertension. clonidine hydrochloride tablets may be employed alone or concomitantly with other antihypertensive agents. clonidine hydrochloride tablets should not be used in patients with known hypersensitivity to clonidine (see precautions ).

미국 - 영어 - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - clonidine hydrochloride (unii: w76i6xxf06) (clonidine - unii:mn3l5rmn02) - clonidine hydrochloride 0.2 mg - clonidine hydrochloride tablets, usp are indicated in the treatment of hypertension. clonidine hydrochloride tablets may be employed alone or concomitantly with other antihypertensive agents. clonidine hydrochloride tablets should not be used in patients with known hypersensitivity to clonidine (see precautions ).

미국 - 영어 - NLM (National Library of Medicine)

ajanta pharma usa inc. - clonidine hydrochloride (unii: w76i6xxf06) (clonidine - unii:mn3l5rmn02) - clonidine hydrochloride 0.1 mg - clonidine hydrochloride extended-release is indicated for the treatment of attention deficit hyperactivity disorder (adhd) as monotherapy and as adjunctive therapy to stimulant medications [see clinical studies (14)] . clonidine hydrochloride extended-release tablets are contraindicated in patients with a history of a hypersensitivity reaction to clonidine. reactions have included generalized rash, urticaria, and angioedema [see adverse reactions (6)] .  pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to adhd medications, including clonidine hydrochloride extended-release tablets, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for adhd medications at 1-866-961-2388 or visiting https://womensmentalhealth.org/adhd-medications/ . risk summary prolonged experience with clonidine in pregnant women over several decades, based on published literature, including controlled trials

미국 - 영어 - NLM (National Library of Medicine)

xiamen lp pharmaceutical co., ltd. - clonidine hydrochloride (unii: w76i6xxf06) (clonidine - unii:mn3l5rmn02) - clonidine hydrochloride 0.1 mg - clonidine hydrochloride extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (adhd) as monotherapy and as adjunctive therapy to stimulant medications [see clinical studies (14)] . clonidine hydrochloride extended-release tablets are contraindicated in patients with a history of a hypersensitivity reaction to clonidine. reactions have included generalized rash, urticaria, and angioedema [see adverse reactions (6)] . pregnancy category c: risk summary there are no adequate or well-controlled studies with clonidine hydrochloride extended-release tablets in pregnant women. in animal embryofetal studies, increased resorptions were seen in rats and mice administered oral clonidine hydrochloride from implantation through organogenesis at 10 and 5 times, respectively, the maximum recommended human dose (mrhd). no embryotoxic or teratogenic effects were seen in rabbits administered ora

미국 - 영어 - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - clozapine (unii: j60ar2ikic) (clozapine - unii:j60ar2ikic) - clozapine 12.5 mg - clozapine orally disintegrating tablets are indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. because of the risks of severe neutropenia and of seizure associated with their use, clozapine orally disintegrating tablets should be used only in patients who have failed to respond adequately to standard antipsychotic treatment [see warnings and precautions (5.1, 5.5)]. the effectiveness of clozapine orally disintegrating tablets in treatment-resistant schizophrenia was demonstrated in a 6-week, randomized, double-blind, active-controlled study comparing clozapine orally disintegrating tablets and chlorpromazine in patients who had failed other antipsychotics [see clinical studies (14.1)]. clozapine orally disintegrating tablets are indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior

미국 - 영어 - NLM (National Library of Medicine)

teva pharmaceuticals usa inc - clozapine (unii: j60ar2ikic) (clozapine - unii:j60ar2ikic) - clozapine 12.5 mg - clozapine odt is indicated for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. because of the risks of severe neutropenia and of seizure associated with its use, clozapine odt should be used only in patients who have failed to respond adequately to standard antipsychotic treatment [see warnings and precautions (5.1, 5.5 )] . the effectiveness of clozapine in treatment-resistant schizophrenia was demonstrated in a 6-week, randomized, double-blind, active-controlled study comparing clozapine and chlorpromazine in patients who had failed other antipsychotics [see clinical studies (14.1 )] . clozapine odt is indicated for reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior, based on history and recent clinical state. suicidal behavior refers to actions by a patient that put him/herself at risk for death. the

미국 - 영어 - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - clonidine hydrochloride (unii: w76i6xxf06) (clonidine - unii:mn3l5rmn02) - clonidine hydrochloride 100 ug in 1 ml - clonidine hydrochloride injection, usp is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. epidural clonidine is more likely to be effective in patients with neuropathic pain than somatic or visceral pain (see clinical pharmacology: clinical trials). the safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid analgesia. other use is of unproven safety and is not recommended. in a rare patient, the potential benefits may outweigh the known risks (see warnings). clonidine hydrochloride injection is contraindicated in patients with a history of sensitization or allergic reactions to clonidine. epidural administration is contraindicated in the presence of an injection site infection, in patients on anticoagulant therapy, and in those with a bleeding diathesis. administration of clonidine hydrochloride injection above the c4 der

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

viatris limited - clonidine 2.52mg equivalent to 0.1 mg/24hr - transdermal patch - 0.1 mg/24h - active: clonidine 2.52mg equivalent to 0.1 mg/24hr excipient: adhesive 8400e/000 colloidal silicon dioxide durotak 87-613a ethylenevinylacetate copolymer heptane light liquid paraffin no tox ink brown- fgn4476 - clonidine transdermal system usp is indicated for the treatment of mild to moderate hypertension. it can be used as monotherapy or concomitantly with other antihypertensive agents if required to enhance hypotensive effect.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

viatris limited - clonidine 5.04mg equivalent to 0.2 mg/24hr - transdermal patch - 0.2 mg/24h - active: clonidine 5.04mg equivalent to 0.2 mg/24hr excipient: adhesive 8400e/000 colloidal silicon dioxide durotak 87-613a ethylenevinylacetate copolymer heptane light liquid paraffin no tox ink brown- fgn4476 - clonidine transdermal system usp is indicated for the treatment of mild to moderate hypertension. it can be used as monotherapy or concomitantly with other antihypertensive agents if required to enhance hypotensive effect.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

viatris limited - clonidine 7.56mg equivalent to 0.3mg/24hr - transdermal patch - 0.3 mg/24h - active: clonidine 7.56mg equivalent to 0.3mg/24hr excipient: adhesive 8400e/000 colloidal silicon dioxide durotak 87-613a ethylenevinylacetate copolymer heptane light liquid paraffin no tox ink brown- fgn4476 - clonidine transdermal system usp is indicated for the treatment of mild to moderate hypertension. it can be used as monotherapy or concomitantly with other antihypertensive agents if required to enhance hypotensive effect.